Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2026)
Prime Medicine (PRME) posted Net Income towards Common Stockholders of -$49.1 million for Q1 2026, down 6.6% on a QoQ basis from -$46.1 million in Q4 2025, and up 5.33% year-over-year from -$46.6 million in Q1 2025.
Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Prime Medicine's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$49.1 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 5.33% year-over-year to -$49.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.4 million (up 1.8% YoY) and the FY2025 annual result came in at -$201.1 million, down 2.69% from the prior year.
- Net Income towards Common Stockholders was -$49.1 million for Q1 2026 at Prime Medicine, down from -$46.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$30.1 million in Q1 2022 and bottomed at -$65.6 million in Q4 2023.
- A 5-year average of -$46.3 million and a median of -$46.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 41.4% — and 2023, when it sank 61.69%.
- Prime Medicine's Net Income towards Common Stockholders stood at -$40.6 million in 2022, then sank by 61.69% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then dropped by 9.0% to -$46.1 million in 2025, then declined by 6.6% to -$49.1 million in 2026.
- Business Quant data shows PRME's Net Income towards Common Stockholders at -$49.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$50.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Prime Medicine | 539.26 Mn | 539.26 Mn | - | -49.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.12 Mn |
| Dec 31, 2025 | -46.08 Mn |
| Sep 30, 2025 | -50.58 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.71 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -40.60 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -35.64 Mn |
| Mar 31, 2022 | -30.06 Mn |
| Dec 31, 2021 | -69.27 Mn |
| Sep 30, 2021 | -22.78 Mn |